Association Between Temozolomide Resistance and Long Non-Coding RNA Expression Profiles in Glioblastoma Cell Lines
Zuzana Hudáková, Ľuboš Hudák, Zuzana Hatoková, Peter Račay, Jozef Hatok · 2026
Read Association Between Temozolomide Resistance and Long Non-Coding RNA Expression Profiles in Glioblastoma Cell Lines by Zuzana Hudáková, Ľuboš Hudák, Zuzana Hatoková, Peter Račay, Jozef Hatok (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13517041.txt.
Description
Zuzana Hudáková and four colleagues link long non-coding RNAs to drug resistance in glioblastoma in a 2026 cell study. The standard drug temozolomide fails often against this brain tumour. Three tumour cell lines with different drug sensitivity, plus normal star-shaped brain cells, were exposed to the drug for up to three days. The team tracked survival, cell-cycle behaviour, a repair protein called MGMT, and nine candidate RNA regulators.
The A172 line proved most sensitive and the T98G line most resistant. Sensitive cells jammed in the run-up to division, while resistant cells barely reacted and carried far more MGMT. RNA patterns split the lines clearly: MALAT1 fell across the board, while NCK1-AS1 surged, above all in the resistant line. Drug exposure itself shifted several regulators, hinting at active adaptation. Hudáková's team names four RNAs as candidate markers and targets for tackling resistance.
Catalog record
| CREATOR | Zuzana Hudáková, Ľuboš Hudák, Zuzana Hatoková, Peter Račay, Jozef Hatok |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |